drugset
drugset / Trial / NCT06572397

Open-Label Study of Safety of H1337 in Healthy Volunteers

NCT06572397 ↗

Phase 1 Completed 17 enrolled D. Western Therapeutics Institute, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The trial will evaluate the safety of one dose regimen of H-1337 \[1% twice daily (b.i.d.)\] in both eyes in healthy volunteers.

Timeline

Start
2024-09-16
Primary completion
2024-10-14
Completion
2024-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject H-1337 Unknown 1 % Other

Indications

ocular hypertension open-angle glaucoma